Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma.
circulating tumour DNA (ctDNA), biomarkers
intratumoural heterogeneity
liquid biopsy
molecular resistance
pancreatic cancer
personalised oncology
targeted therapy
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
18 Jul 2019
18 Jul 2019
Historique:
received:
28
05
2019
revised:
03
07
2019
accepted:
16
07
2019
entrez:
21
7
2019
pubmed:
22
7
2019
medline:
22
7
2019
Statut:
epublish
Résumé
Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circulating biomarkers that have potential clinical application as tumour markers, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), exosomes and circulating tumour proteins. This review will focus on the development of ctDNA as a non-invasive liquid biopsy, with its high sensitivity and specificity having potential clinical applications in pancreatic cancer. These include a role in screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and for patients with advanced disease; tumour genotyping and monitoring treatment response. Prospective randomised adjuvant clinical trials are currently underway, exploring the impact of ctDNA-guided adjuvant therapy decisions. In this review, we provide perspectives on the current literature and considerations of future directions.
Identifiants
pubmed: 31323810
pii: jpm9030037
doi: 10.3390/jpm9030037
pmc: PMC6789869
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Br J Cancer. 2017 Sep 26;117(7):1017-1025
pubmed: 28772284
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Mol Oncol. 2016 Apr;10(4):635-43
pubmed: 26725968
Pancreas. 2009 Jul;38(5):534-41
pubmed: 19295453
Cancer Res. 2006 Jan 15;66(2):1208-17
pubmed: 16424060
Clin Cancer Res. 2015 Oct 1;21(19):4473-81
pubmed: 26023084
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207
pubmed: 28874546
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Clin Cancer Res. 1998 Jun;4(6):1527-32
pubmed: 9626473
Cancer Discov. 2016 Feb;6(2):147-153
pubmed: 26644315
Cancer. 2015 Jul 1;121(13):2271-80
pubmed: 25823825
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5
pubmed: 21586637
Gut. 2012 Jul;61(7):1085-94
pubmed: 21749982
Presse Med. 2019 Mar;48(3 Pt 2):e113-e123
pubmed: 30878335
Cancer Discov. 2018 Feb;8(2):164-173
pubmed: 29196463
Cancer Discov. 2015 Oct;5(10):1040-8
pubmed: 26109333
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Cancer Res. 1977 Mar;37(3):646-50
pubmed: 837366
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Clin Epigenetics. 2016 Nov 16;8:117
pubmed: 27891190
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Cancer Res. 1998 Feb;4(2):271-5
pubmed: 9516910
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
Cancer Res. 2001 Feb 15;61(4):1659-65
pubmed: 11245480
Ann Oncol. 2009 Aug;20(8):1387-96
pubmed: 19502533
Cancer. 2010 Apr 1;116(7):1674-80
pubmed: 20143430
Br J Cancer. 2002 Aug 27;87(5):551-4
pubmed: 12189555
Gene. 2018 Dec 30;679:328-334
pubmed: 30227250
World J Gastroenterol. 2016 Jan 14;22(2):776-89
pubmed: 26811624
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Ann Surg Oncol. 2001 Dec;8(10):758-65
pubmed: 11776488
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
Cell. 1988 May 20;53(4):549-54
pubmed: 2453289
Cancer J. 2017 Nov/Dec;23(6):333-342
pubmed: 29189329
C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3
pubmed: 18875018
Cancer Invest. 2015 Mar;33(3):78-85
pubmed: 25647443
Semin Radiat Oncol. 2014 Apr;24(2):105-12
pubmed: 24635867
Ann Oncol. 2018 Dec 1;29(12):2348-2355
pubmed: 30346475
J Gastroenterol. 2004 Jan;39(1):56-60
pubmed: 14767735
APMIS. 2019 May;127(5):329-336
pubmed: 30784124
JAMA. 2012 Jul 11;308(2):147-56
pubmed: 22782416
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424
pubmed: 30796368
J Genet Genomics. 2018 Feb 20;45(2):79-85
pubmed: 29502957
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Cell Biol Toxicol. 2019 Aug;35(4):333-343
pubmed: 30771135
Oncol Lett. 2019 Feb;17(2):1409-1416
pubmed: 30675194
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Clin Oncol. 2018 Sep;15(9):577-586
pubmed: 29968853
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Am J Med Sci. 2013 Sep;346(3):175-80
pubmed: 23360791
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Eur J Surg Oncol. 2010 Jul;36(7):657-62
pubmed: 20542658
Nat Commun. 2015 Jul 07;6:7686
pubmed: 26154128
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102
Clin Cancer Res. 2017 Jan 1;23(1):116-123
pubmed: 27993964
Pancreas. 2002 Nov;25(4):336-41
pubmed: 12409826